{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:44:56Z","timestamp":1773297896698,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Cannabidiol is a cannabinoid\u2010derived product that has recently been approved for the treatment of pharmacoresistant seizures in patients with epileptic encephalopathies such as Dravet Syndrome and Lennox\u2010Gastaut Syndrome. Short\u2010term side effects of cannabidiol are well know and well\u2010documented in the clinical trials that lead to its approval. Generally, is a well tolerated drug with transitory, dose\u2010dependent mild to moderate effects like somnolence, decreased appetite or diarrhoea. However severe life\u2010threatening reactions can also occur, and are often related to the non\u2010controlled toxic combination with other antiseizure drugs that are widely used in this type of patients like sodium valproate or clobazam. In this brief review we summarize the available data about the short\u2010term adverse events of cannabidiol. Further studies are required to assess the long\u2010term outcome and final resolution of these conditions regarding safety of these patients.<\/jats:p>","DOI":"10.1684\/epd.2019.1125","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T16:24:23Z","timestamp":1706027063000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adverse effects of cannabinoids"],"prefix":"10.1002","volume":"22","author":[{"given":"Carla","family":"Anciones","sequence":"first","affiliation":[{"name":"Epilepsy Program, Neurology Department Hospital Ruber Internacional  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gil\u2010Nagel","sequence":"additional","affiliation":[{"name":"Epilepsy Program, Neurology Department Hospital Ruber Internacional  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1141"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00379-8"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611618"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005254"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714631"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14628"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13852"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13060"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816669450"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13499"},{"issue":"1","key":"e_1_2_5_12_1","first-page":"S16","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Johannessen Landmark C.","year":"2020","journal-title":"Epileptic Disord."},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000363"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0558-9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.621"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2013.849268"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30136-3"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318283b49a"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2019.1125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T16:42:11Z","timestamp":1706028131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2019.1125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1684\/epd.2019.1125"],"URL":"https:\/\/doi.org\/10.1684\/epd.2019.1125","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"2020-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}